Relief Therapeutics
Swiss biopharmaceutical company developing and commercializing novel therapies for rare and serious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $5.8m | Post IPO Debt | |
| Total Funding | 000k | ||
| CHF | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 83 % | (1 %) | 40 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (1011 %) | (405 %) | (279 %) | (59 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (1045 %) | (835 %) | (1627 %) | (203 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 204 % | 22 % | 16 % |
Source: Company filings or news article
Related Content
Relief Therapeutics is a Swiss-based, commercial-stage biopharmaceutical company focused on the development and commercialization of innovative, patent-protected therapies targeting specialty, rare, and ultra-rare diseases. The company collaborates with selected partners to bring novel treatments to market, aiming to address significant unmet medical needs in niche patient populations. Relief Therapeutics leverages its expertise in drug development and regulatory affairs to advance a portfolio of products designed to improve outcomes and quality of life for patients with limited therapeutic options.
Keywords: Relief Therapeutics, Swiss biopharmaceutical, commercial-stage, novel therapies, patent-protected, specialty diseases, rare diseases, ultra-rare diseases, drug development, partnerships, unmet medical needs
Investments by Relief Therapeutics
Edit
